Open tTG ELISA

Upon substrate binding TG2 dramatically changes its structure (Pinkas et al., PLoS Biol. 2007). By reacting TG2 with a novel irreversible inhibitor we could stabilize TG2 in the open conformation which we branded Open tTG™.

Open tTG™ – it fits the antigen to the autoantibody – is the key to detect seronegative or borderline celiac disease patients. Used as antigen in ELISA-based diagnostics, Open tTG™ (E006/E007) is superior to the so far used closed conformation TG2 especially for patient's sera with low or negative tTG autoantibody-titers (Lindfors et al., J. Clin. Immunol. 2011, 31:436-42).

For the purified non coated protein products
Open tTGTM, Inhibited TG3 and Inhibited TG6 please refer to Section: Transglutaminases
 


Art. No.
Name
Quantity
Price
E006 ZediXclusive Open tTGTM-ab ELISA (IgA)
Open tTGTM tissue transglutaminase (TG2) ELISA Kit (IgA)
1 kit/96 wells
520 €
E007 ZediXclusive Open tTGTM-ab ELISA (IgG)
Open tTGTM tissue transglutaminase (TG2) ELISA Kit (IgG)
1 kit/96 wells
520 €

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland